Pfiz­er, US Army nab a new ap­proval for a decades-old vac­cine

It won’t make Pfiz­er even a mi­nus­cule frac­tion of what its oth­er new vac­cines have and will earn, but the New York drug­mak­er has got­ten yet an­oth­er in­oc­u­la­tion ap­proved by the FDA.

Pfiz­er an­nounced Mon­day that US reg­u­la­tors have OK’d Tico­v­ac, the com­pa­ny’s vac­cine for tick-borne en­cephali­tis, a virus that in­fects the brain and ner­vous sys­tem and can some­times cause long-term cog­ni­tive, skele­tal or mus­cu­lar ef­fects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.